Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 03, 2015 2:22 AM ET

Biotechnology

Company Overview of Affimed N.V.

Company Overview

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company’s product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor v...

Technologiepark

Im Neuenheimer Feld 582

Heidelberg,  69120

Germany

Founded in 2000

52 Employees

Phone:

49 6221 65307 0

Fax:

49 6221 65307 77

Key Executives for Affimed N.V.

Chief Executive Officer and Member of Management Board
Age: 53
Total Annual Compensation: $297.0K
Chief Financial Officer and Member of Management Board
Age: 47
Total Annual Compensation: $190.0K
Chief Medical Officer and Member of Management Board
Age: 52
Total Annual Compensation: $352.0K
Compensation as of Fiscal Year 2014.

Affimed N.V. Key Developments

Affimed N.V.(NasdaqGM:AFMD) added to Russell 2000 Index

Affimed N.V. will be added to Russell 2000 Index

Affimed N.V.(NasdaqGM:AFMD) added to Russell 3000 Index

Affimed N.V. will be added to the Russell 3000 Index.

Affimed N.V. Announces Opening of US Operations; Announces Executive Appointment for New Operations

Affimed N.V. announced that it has established operations in the United States. The company also announced that Caroline Stewart and Dr. Oscar Kashala have joined the company as Head of Investor Relations & Communication and Vice President, Medical US respectively. Caroline brings nearly twenty years of combined experience on Wall Street and in the pharmaceutical industry to the company. Oscar is a biopharmaceutical executive with expertise in early to late-stage development of oncology and infectious diseases products. He held positions of increasing responsibility at Cambridge Biotech/Aquila Biopharmaceuticals, Lexigen Pharmaceuticals, Millennium Pharmaceuticals, and EMD Serono, where he led the efforts to develop immunotherapy for solid tumors and hematologic cancers.

Similar Private Companies By Industry

Company Name Region
Merck Serono GmbH Europe
multiBIND biotec GmbH Europe
Metabolomic Discoveries GmbH Europe
AdnaGen AG Europe
Epiontis GmbH Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 2, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Affimed N.V., please visit www.affimed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.